Screening for sickle cell disease in newborns: a systematic review

Table 4 Results on mortality

Study	Age	Intervention		Control		Intervention vs. control
Study	Age	n	Mortality rate^a (%) [95% CI]	n	Mortality rate^a (%) [95% CI]	OR^b	[95% CI]^b	p value^b
King et al. [26]		395^c		105
	1st year of life	n.a.	0.01 [0.01; 0.03]	n.a.	0.10 [0.04; 0.15]	0.09	[0.03; 0.30]	< 0.001
	2nd year of life	n.a.	0.01 [0.01; 0.03]	n.a.	0.14 [0.07; 0.20]	0.06	[0.02; 0.20]	< 0.001
	3rd year of life	n.a.	0.01 [0.01; 0.03]	n.a.	0.17 [0.10; 0.25]	0.05	[0.02; 0.15]	< 0.001
	5th year of life	n.a.	0.02 [0.01; 0.04]	n.a.	0.19 [0.12; 0.27]	0.09	[0.04; 0.22]	< 0.001
	10th year of life	n.a.	0.09 [0.02; 0.27]	n.a.	0.23 [0.15; 0.32]	0.33	[0.07; 1.64]	0.176

CI confidence interval, n number of participants evaluated, n.a. not available, OR odds ratio
^aIQWiG’s own calculation of the mortality rate from data on survival probability which is given in King et al. [26]. Information on the method used to estimate survival probability was missing in King et al. [26]. No absolute numbers of deaths or survivals available
^bIQWiG´s own calculation: approximately determined from the data on mortality rates in the groups and self-estimated number n
^cParents of 40 of the 435 newborns did not attend the initial consultation. Therefore, 395 newborns were included in the intervention programme

ISSN: 2046-4053